(NHC) National HealthCare - Ratings and Ratios
Nursing Homes, Assisted Living, Memory Care, Home Care
NHC EPS (Earnings per Share)
NHC Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 28.0% |
| Value at Risk 5%th | 44.1% |
| Reward | |
|---|---|
| Sharpe Ratio | 0.09 |
| Alpha | -9.94 |
| Character | |
|---|---|
| Hurst Exponent | 0.525 |
| Beta | 0.675 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.40% |
| Mean DD | 10.11% |
Description: NHC National HealthCare August 13, 2025
National HealthCare Corporation (NHC) is a healthcare company operating in the United States, specifically in the Health Care Facilities sub-industry. The companys stock is listed on the NYSE MKT exchange under the ticker symbol NHC.
To evaluate NHCs performance, key financial metrics such as Return on Equity (ROE) and Price-to-Earnings (P/E) ratio are crucial. NHCs ROE stands at 11.03%, indicating a relatively stable return for shareholders. The P/E ratio is 13.96, suggesting that the stock may be undervalued compared to its earnings. Additionally, the Market Capitalization of $1.49 billion categorizes NHC as a mid-cap stock, potentially offering a balance between growth and stability.
The healthcare facilities sector is driven by demographic trends, such as an aging population, and regulatory changes. Key economic drivers include occupancy rates, Medicare/Medicaid reimbursement rates, and the overall demand for healthcare services. To assess NHCs operational performance, metrics such as revenue growth, same-facility sales growth, and operating margins are essential. A thorough analysis of these KPIs can help identify areas of strength and potential improvement.
NHCs stock price movements can be analyzed in the context of its volatility, measured by the Average True Range (ATR). A relatively low beta of 0.591 indicates that NHCs stock price is less sensitive to market fluctuations, potentially making it a defensive investment. To further evaluate the stocks potential, an examination of its trading volume, short interest, and institutional ownership can provide valuable insights.
NHC Stock Overview
| Market Cap in USD | 1,973m |
| Sub-Industry | Health Care Facilities |
| IPO / Inception | 1987-01-20 |
| Return 12m vs S&P 500 | -14.4% |
| Analyst Rating | - |
NHC Dividends
| Dividend Yield | 1.91% |
| Yield on Cost 5y | 4.18% |
| Yield CAGR 5y | 3.86% |
| Payout Consistency | 75.4% |
| Payout Ratio | 62.9% |
NHC Growth Ratios
| CAGR | 33.84% |
| CAGR/Max DD Calmar Ratio | 1.01 |
| CAGR/Mean DD Pain Ratio | 3.35 |
| Current Volume | 54.1k |
| Average Volume | 59.3k |
Piotroski VR‑10 (Strict, 0-10) 9.5
| Net Income (101.2m TTM) > 0 and > 6% of Revenue (6% = 89.2m TTM) |
| FCFTA 0.10 (>2.0%) and ΔFCFTA 3.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 9.55% (prev 16.09%; Δ -6.53pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.12 (>3.0%) and CFO 181.1m > Net Income 101.2m (YES >=105%, WARN >=100%) |
| Net Debt (128.1m) to EBITDA (151.4m) ratio: 0.85 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.50 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (15.7m) change vs 12m ago -0.02% (target <= -2.0% for YES) |
| Gross Margin 53.67% (prev 37.93%; Δ 15.74pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 96.34% (prev 78.68%; Δ 17.67pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 13.52 (EBITDA TTM 151.4m / Interest Expense TTM 7.90m) >= 6 (WARN >= 3) |
Altman Z'' 4.50
| (A) 0.09 = (Total Current Assets 424.4m - Total Current Liabilities 282.4m) / Total Assets 1.52b |
| (B) 0.54 = Retained Earnings (Balance) 818.1m / Total Assets 1.52b |
| (C) 0.07 = EBIT TTM 106.8m / Avg Total Assets 1.54b |
| (D) 1.59 = Book Value of Equity 817.1m / Total Liabilities 513.9m |
| Total Rating: 4.50 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 80.86
| 1. Piotroski 9.50pt = 4.50 |
| 2. FCF Yield 7.25% = 3.63 |
| 3. FCF Margin 9.88% = 2.47 |
| 4. Debt/Equity 0.12 = 2.49 |
| 5. Debt/Ebitda 0.85 = 1.97 |
| 6. ROIC - WACC (= 3.72)% = 4.65 |
| 7. RoE 9.98% = 0.83 |
| 8. Rev. Trend 94.85% = 7.11 |
| 9. EPS Trend 64.19% = 3.21 |
What is the price of NHC shares?
Over the past week, the price has changed by +8.04%, over one month by +11.36%, over three months by +27.10% and over the past year by -1.40%.
Is National HealthCare a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of NHC is around 141.66 USD . This means that NHC is currently overvalued and has a potential downside of 8.33%.
Is NHC a buy, sell or hold?
What are the forecasts/targets for the NHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.2 | -95.3% |
| Analysts Target Price | 6.2 | -95.3% |
| ValueRay Target Price | 157.3 | 20.3% |
NHC Fundamental Data Overview November 10, 2025
P/E Trailing = 19.5948
P/S = 1.3148
P/B = 1.8475
Beta = 0.675
Revenue TTM = 1.49b USD
EBIT TTM = 106.8m USD
EBITDA TTM = 151.4m USD
Long Term Debt = 129.5m USD (from longTermDebt, last fiscal year)
Short Term Debt = 40.7m USD (from shortTermDebt, last quarter)
Debt = 128.1m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 128.1m USD (from netDebt column, last quarter)
Enterprise Value = 2.03b USD (1.97b + Debt 128.1m - CCE 76.1m)
Interest Coverage Ratio = 13.52 (Ebit TTM 106.8m / Interest Expense TTM 7.90m)
FCF Yield = 7.25% (FCF TTM 146.9m / Enterprise Value 2.03b)
FCF Margin = 9.88% (FCF TTM 146.9m / Revenue TTM 1.49b)
Net Margin = 6.81% (Net Income TTM 101.2m / Revenue TTM 1.49b)
Gross Margin = 53.67% ((Revenue TTM 1.49b - Cost of Revenue TTM 689.0m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 39.28%)
Tobins Q-Ratio = 1.33 (Enterprise Value 2.03b / Total Assets 1.52b)
Interest Expense / Debt = 1.14% (Interest Expense 1.46m / Debt 128.1m)
Taxrate = -24.63% (negative due to tax credits) (-13.4m / 54.4m)
NOPAT = 133.1m (EBIT 106.8m * (1 - -24.63%)) [negative tax rate / tax credits]
Current Ratio = 1.50 (Total Current Assets 424.4m / Total Current Liabilities 282.4m)
Debt / Equity = 0.12 (Debt 128.1m / totalStockholderEquity, last quarter 1.05b)
Debt / EBITDA = 0.85 (Net Debt 128.1m / EBITDA 151.4m)
Debt / FCF = 0.87 (Net Debt 128.1m / FCF TTM 146.9m)
Total Stockholder Equity = 1.01b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.64% (Net Income 101.2m / Total Assets 1.52b)
RoE = 9.98% (Net Income TTM 101.2m / Total Stockholder Equity 1.01b)
RoCE = 9.33% (EBIT 106.8m / Capital Employed (Equity 1.01b + L.T.Debt 129.5m))
RoIC = 11.79% (NOPAT 133.1m / Invested Capital 1.13b)
WACC = 8.07% (E(1.97b)/V(2.10b) * Re(8.50%) + D(128.1m)/V(2.10b) * Rd(1.14%) * (1-Tc(-0.25)))
Discount Rate = 8.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.57%
[DCF Debug] Terminal Value 77.99% ; FCFE base≈126.1m ; Y1≈138.1m ; Y5≈175.6m
Fair Price DCF = 180.8 (DCF Value 2.80b / Shares Outstanding 15.5m; 5y FCF grow 10.86% → 3.0% )
EPS Correlation: 64.19 | EPS CAGR: 161.1% | SUE: N/A | # QB: 0
Revenue Correlation: 94.85 | Revenue CAGR: 13.16% | SUE: N/A | # QB: 0
Additional Sources for NHC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle